Disease activity and joint damage progression in early rheumatoid arthritis: relation to IgG, IgA, and IgM rheumatoid factor

K B Eberhardt, L Truedsson, H Pettersson, B Svensson, L Stigsson, J L Eberhardt, F A Wollheim

Abstract
The clinical and biochemical correlations with joint damage progression over two years in a consecutive group of 68 patients with rheumatoid arthritis with disease duration of less than two years are reported. Joint damage was assessed with Larsen's severity scale and a measure of change in progression rate constructed. Initial haemoglobin concentration, Ritchie index, and Waaler-Rose titre in combination accounted for one third of the variance in joint damage progression. Rheumatoid factor (RF) concentrations were followed with enzyme linked immunosorbent assays (ELISAs) for IgG RF, IgA RF, and IgM RF. The RF concentrations, except IgG RF, decreased with time; significant correlations between RFs and disease activity were few and barely clinically useful. After two years IgG RF correlated significantly with a radiological score if early non-erosive changes were omitted. All RFs tended to correlate better with this radiological score at all three observation points. Analyses of the change in progression rate indicated a time delay between development of radiographic changes and increase of IgG RF. These results suggest an indirect relation between RFs and joint damage. Clinical and biochemical improvements in early RA occur despite joint damage progression, and conventional markers have insufficient predictive value.

Enzyme linked immunosorbent assays (ELISAs) permit the detection and measurement of rheumatoid factors (RFs) of various immunoglobulin classes. The clinical value of RF isotype measurements is currently discussed. We have previously reported that RFs assayed at the start of a prospective study of early rheumatoid arthritis were not associated with erosive disease during the first two years. Measures of disease activity recorded at the same time did not correlate with the RF concentrations. This study has now been expanded to evaluate a possible association between severity of radiological changes and RFs and to determine whether fluctuations in RF concentrations might reflect fluctuations in disease activity assessed serially over two years.

Patients and methods
Seventy one patients from primary care units in the area with definite rheumatoid arthritis and disease duration of less than two years were enrolled in the study. During a follow up of 24 months two patients died owing to pulmonary carcinoma, and another patient was reclassified as psoriatic arthritis. The remaining 68 patients (26 men, 42 women) had a mean (SD) age of 56.1 (14.1) years and mean (SD) disease duration at the start of the study of 11.8 (6.8) months.

During the study period about half of the patients were treated with slow acting antirheumatic drugs, mostly antimalarial drugs (20 patients) or n-penicillamine (10 patients).

CLINICAL EVALUATION
The patients were evaluated at regular intervals by clinical and laboratory measures as previously described. Briefly, the articular disease was estimated by the Ritchie index and an active joint count. Grip strength was measured with a sphygmomanometer (mean of readings for right and left hand). Functional capacity was assessed with a validated Swedish version of the Stanford Health Assessment Questionnaire disability index.

Pain during the preceding week was recorded on a visual analogue scale.

RADIOLOGICAL EVALUATION
Radiographic examinations of hands, wrists, and feet were performed at study start and after 12 and 24 months. All radiographs were evaluated by one experienced radiologist and the findings were scored using the method described by Larsen. Thus each joint was compared with standard reference films and assigned a score between 0 (normal) and 5 (mutilating changes). Severity stage 1 corresponded to non-erosive changes—that is, soft tissue swelling and periarticular osteoporosis, and stages 2-4 corresponded to increasing degrees of erosions and joint space narrowing. Thirty two joints were evaluated: the wrists, the metacarpophalangeal joints I-V, interphalangeal joint I, proximal interphalangeal joints II-V of the hands and the interphalangeal joint I and metatarsophalangeal joints II-V of the feet. The wrist score was multiplied by five and all the scores added up, together forming the joint damage index. In addition, a modified index omitting severity stage 1 was calculated.

In analyses of radiological outcome the absolute difference between scores after two years and at study start was taken into account. A new radiological measure assessing the change in progression rate between the first and second 12 month period was constructed according to the formula illustrated in the figure. The usefulness of the new index was also analysed.
Disease activity and joint damage in early RA

**RHEUMATOID FACTOR MEASUREMENTS**

Rheumatoid factors of IgG, IgA, and IgM classes were analysed. Briefly, human serum albumin was adsorbed onto the plastic surface of microtitre wells and rabbit IgG antibodies specific for the human serum albumin were added. After addition of the test sample bound RFs were detected by enzyme labelled immunoglobulin class specific F(ab')2 fragments.

The results of the ELISAs were expressed as arbitrary units (AU) compared with a local standard said to contain 1000 AU/ml. Concentrations of 4 AU/ml or more of IgA RF and IgM RF and 6 AU/ml or more of IgG RF were considered positive.

An IgG fraction was used for sensitisation of sheep red cells and a Waaler-Rose test performed according to standard procedures. A titre of 1/64 corresponding to 50 IU/ml10 was considered positive.

**STATISTICAL ANALYSES**

Differences between clinical and laboratory measures obtained at 0, 12, and 24 months were evaluated with Wilcoxon's test for paired data. Correlations were estimated with Spearman’s rank correlation coefficient method. Owing to the large number of correlations calculated the level of significance was set at 0.002. Correlations between RFs and different measures of disease activity were calculated both for the absolute values at 0, 12, and 24 months and for changes between the observation times.

Backward stepwise multiple regression was performed using a radiological outcome measure as dependent variable and the clinical and laboratory measures as independent variables. Variables contributing with F <4.0 were excluded from the regression. The validity of the regressions was assessed by residual analyses.

**RESULTS**

Table 1 shows the results of clinical, laboratory, and radiological assessments at 0, 12, and 24 months. Most clinical and laboratory measures improved with time. In contrast, the radiological status deteriorated.

More than half of the sera contained all antiglobulin isotypes simultaneously and about 15% of the sera contained a mixture of IgA RF and IgM RF. No serum containing only IgA RF was found. Table 2 shows the concentrations of the RFs. The rheumatoid factor concentrations, with the exception of IgG RF, were significantly lower at the end. RF concentrations correlated significantly with each other throughout the study, though all correlations decreased with time. No significant correlations were found between the absolute values of the RF concentrations and various measures of disease activity at the three observation points. In the analysis of changes between 0 and 12 months IgM RF and Waaler-Rose tests correlated significantly with C reactive protein (r =0.44 for both correlations). Table 3 shows the correlations between different RF isotypes and the absolute values of the ordinary and modified joint damage scores, respectively, over time. IgG RF correlated significantly with the modified score after two years. All the RF isotypes tended to correlate better with the modified score at all three observation points. C reactive protein concentrations are shown in Table 2.

**Table 1** Some clinical and laboratory measures at 0, 12, and 24 months. Results given as medians (1st; 3rd quartile)

<table>
<thead>
<tr>
<th>Measure</th>
<th>Month 0</th>
<th>*p Value 0 v 12 months</th>
<th>Month 12</th>
<th>*p Value 12 v 24 months</th>
<th>Month 24</th>
<th>*p Value 12 v 24 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active joint count</td>
<td>8 (3; 13)</td>
<td>&lt;0.01</td>
<td>5 (1; 11)</td>
<td>&lt;0.001</td>
<td>3 (1; 6)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Grip strength (mmHg)</td>
<td>91 (60; 150)</td>
<td>&lt;0.05</td>
<td>110 (68; 235)</td>
<td>NS</td>
<td>130 (85; 240)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Morning stiffness (min)</td>
<td>60 (20; 120)</td>
<td>NS</td>
<td>60 (60; 120)</td>
<td>NS</td>
<td>52.5 (0; 60)</td>
<td>NS</td>
</tr>
<tr>
<td>Pain (0-3)</td>
<td>1.4 (0.9; 2.1)</td>
<td>NS</td>
<td>1.1 (0.5; 2.7)</td>
<td>NS</td>
<td>0.8 (0; 1; 1.5)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>HAQ† disability-index (0-3)</td>
<td>0.9 (0.5; 1.5)</td>
<td>NS</td>
<td>0.8 (0.4; 1.3)</td>
<td>NS</td>
<td>0.8 (0; 1; 1.3)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Haemoglobin (g/l)</td>
<td>129 (120; 140)</td>
<td>NS</td>
<td>129 (120; 140)</td>
<td>NS</td>
<td>133 (119; 141)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>ESR† (mm/h)</td>
<td>24 (14; 40)</td>
<td>NS</td>
<td>23 (12; 35)</td>
<td>NS</td>
<td>20 (11; 38.5)</td>
<td>NS</td>
</tr>
<tr>
<td>CRP† (mg/l)</td>
<td>&lt;10 (&lt;10; 45)</td>
<td>&lt;0.001</td>
<td>12 (&lt;16; 30; 5)</td>
<td>&lt;0.001</td>
<td>&lt;10 (&lt;10; 22)</td>
<td>NS</td>
</tr>
<tr>
<td>Joint damage index</td>
<td>9 (3; 22)</td>
<td>&lt;0.001</td>
<td>22 (9; 35; 5)</td>
<td>&lt;0.001</td>
<td>30 (5; 19; 46.5)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

*Wilcoxon's test for paired data (two tailed).
†HAQ=Stanford Health Assessment Questionnaire disability index *; ESR=erythrocyte sedimentation rate; CRP=C reactive protein.

**Table 2** Concentrations of rheumatoid factors (RFs) expressed in arbitrary units/ml at study start and after 24 months. Results given as medians (1st; 3rd quartile)

<table>
<thead>
<tr>
<th>Month 0</th>
<th>Month 24</th>
<th>*p Value 0 v 24 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>IgA RF</td>
<td>37.5 (6.5; 74.5)</td>
<td>21 (6; 42)</td>
</tr>
<tr>
<td>IgM RF</td>
<td>92 (30; 147.5)</td>
<td>49 (22; 105)</td>
</tr>
<tr>
<td>IgG RF</td>
<td>12.5 (0; 32)</td>
<td>14 (5; 37)</td>
</tr>
</tbody>
</table>

*Wilcoxon’s test for paired data (two tailed).

**Table 3** Correlations (r,p) over time between the different rheumatoid factor (RF) isotypes and the absolute values of the two radiological scores

<table>
<thead>
<tr>
<th>Observation 1</th>
<th>Observation 2</th>
<th>Observation 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>JDF†</td>
<td>MJD†</td>
<td>JDF‡</td>
</tr>
<tr>
<td>IgA RF</td>
<td>0.05</td>
<td>0.23</td>
</tr>
<tr>
<td>IgM RF</td>
<td>0.07</td>
<td>0.21</td>
</tr>
<tr>
<td>IgG RF</td>
<td>0.17</td>
<td>0.27</td>
</tr>
</tbody>
</table>

* p<0.002.
† r=p<0.002.
‡ r=Spearmans rank correlation coefficient; JDF=joint damage score; MJD=modified joint damage score omitting non-erosive changes.
correlated significantly with the ordinary score at 12 and 24 months \((r=0.41\) and 0.44 respectively). Clinical variables such as morning stiffness, grip strength, and active joint count did not correlate significantly with either score. As might be expected the correlations between the two joint damage indices themselves increased with time \((r=0.81, 0.85, 0.90)\).

Regression analyses were performed for the different observation points separately. A combination of the initial values of the Ritchie index, haemoglobin concentration, and RF explained 32% of the variance in the absolute change of the joint damage index between the start of the study and two years. Age was a confounding factor and was corrected for. Table 4 shows the result of the analysis. The highest correlation obtained for a single variable (haemoglobin) was 0.30 and the combination of variables increased this to 0.57. Twenty five per cent of the variance of the parallel change of the radiological progression rate could be explained by a set of variables—morning stiffness, active joint count, and IgG RF—obtained after 12 months (table 5). It is noteworthy that the correlation with IgG RF was negative. The regression analysis increased the correlation from 0.30 (IgG RF) to 0.46.

**Discussion**

The early symptomatic phase of rheumatoid arthritis has attracted increasing attention in several recent studies in the hopes of defining better prognostic variables\(^1\) to gain therapeutic advantages.\(^1\) Our study aimed at applying sensitive immunochemical assays for RFs and correlating the results with clinical and radiological features.

Some of the patients in this study had been treated with different slow acting antirheumatic drugs, which might have influenced the RF concentrations. The study design did not allow measurement of possible effects.

One third of the variance in the progression of joint damage over two years could be explained by some of the clinical and laboratory variables obtained at the start of the study. The contributing variables were Ritchie index, haemoglobin concentration, and Waaler-Rose titre.

Thus the conventional agglutination test was a more useful indicator of progression rate, though the regression coefficient for the Waaler-Rose test was barely significant.

In analyses of associations between serial changes in RFs and measures of disease activity only a few significant correlations during the first year were obtained, which were of little clinical relevance. This is in accordance with Scott et al., who found no advantage from serial measurements of IgM RFs and IgG RFs in assessing disease activity in patients during 12 months’ treatment with gold or penicillamine.\(^3\)

March et al. investigated the ability of different measures obtained initially to predict articular index after one year in patients with early rheumatoid arthritis.\(^6\) None of IgA RF, IgG RF, or IgM RF contributed to the prediction.

On the other hand, several authors have found RF isotype measurements useful in the assessment of disease activity in patients studied prospectively,\(^17\) though the isotype shown to correlate with disease activity varied between the studies. Some of the variation in the results of the different studies may be due to differences in patient selection. Also some of the studies based their conclusions on a small number of patients. The statistical evaluation of changes over time with many different variables is complicated and various methods have been used, which makes interpretation and comparison difficult. The problem of mass significance also has to be considered and the levels of significance should be set high, which has not always been the case.

In general, the amounts of RFs decreased during the study. An exception were the persisting or even slightly increasing concentrations of IgG RFs reminiscent of the normal class switching sequence during the immunisation process. IgG RFs may be of value to parallel the chronicity of the disease more closely. Similarly, correlation between radiological changes and IgG RF became closer with time.

Only a weak relation between RFs and the degree of radiological change could be shown in this study. The association with IgG RF and erosive disease is supported by the findings of Hannonen et al.\(^2\) In contrast with several other authors,\(^1\) but in agreement with Gioud-Paquet et al.\(^2\) and Hannonen et al.,\(^2\) no relation between IgA RF and erosive disease could be found. Winska Wiloch et al., who compared concentrations of IgA RF and IgM RF at the start of a study of early RA with radiographic changes 10 years later, found significant correlations for both isotypes.\(^6\)

The modified joint damage index, omitting the non-erosive severity stage 1, reflects the irreversible joint abnormalities and thus a later disease stage. The RFs consistently tended to correlate better with this index (table 3). There seems to be a time lag for the association between RFs and radiological changes. In the Larsen classification stage 1 is less certain and an index omitting this stage will therefore be even better, which may contribute to the better correlation. On the other hand, an acute
phase reactant such as CRP correlated best with the ordinary score, indicating that this index better reflects the early inflammatory joint changes.

To obtain a further measure of joint damage progression an index measuring the change in progression rate was constructed. The best regression fit was obtained when variables after one year were analysed. IgG RF contributed most and the correlation was negative, meaning that a high IgG RF reflects a high initial but later decreasing progression rate. This pattern of joint damage progression with an initial high rate followed by a static phase has previously been described in patients with early RA. It seems that the radiological changes preceded the increase of IgG RF concentration. The change in progression rate index may be useful for testing the temporal connection between the disease process and presumed predictive indicators.

The finding of a delayed IgG RF response together with an earlier observation that RFs tended to correlate better with the modified joint damage index suggests that RFs are not participating directly in the joint damage process but are mainly reflecting a later stage when the damage is already done.

In conclusion, it seems that determination of RF isotypes remains a research tool of limited clinical value in assessing patients with rheumatoid arthritis.

This work was supported by grants from the Swedish Rheumatism Association, the King Gustav V 80th Birthday Fund, the Foundation for Aid to the Disabled in Scania, the M Bergwall Trust, Greta and Johan Rockos Trusts, the A Wilberg Trust, the A Osterlund Trust, and the Faculty of Medicine, University of Lund.

Disease activity and joint damage progression in early rheumatoid arthritis: relation to IgG, IgA, and IgM rheumatoid factor.

K B Eberhardt, L Truedsson, H Pettersson, B Svensson, L Stigsson, J L Eberhardt and F A Wollheim

doi: 10.1136/ard.49.11.906

Updated information and services can be found at: [http://ard.bmj.com/content/49/11/906](http://ard.bmj.com/content/49/11/906)

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to: [http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to: [http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to: [http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)